Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.

Autor:	Rancoita PMV; University Centre of Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy., Cugnata F; University Centre of Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy., Gibertoni Cruz AL; Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, United Kingdom., Borroni E; Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Hoosdally SJ; Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, United Kingdom., Walker TM; Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, United Kingdom., Grazian C; Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, United Kingdom., Davies TJ; Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, United Kingdom., Peto TEA; Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, United Kingdom., Crook DW; Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, United Kingdom., Fowler PW; Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, United Kingdom., Cirillo DM; Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy cirillo.daniela@hsr.it.
Jazyk:	angličtina
Zdroj:	Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2018 Aug 27; Vol. 62 (9). Date of Electronic Publication: 2018 Aug 27 (Print Publication: 2018).
DOI:	10.1128/AAC.00344-18
Abstrakt:	The UKMYC5 plate is a 96-well microtiter plate designed by the CRyPTIC Consortium (Comprehensive Resistance Prediction for Tuberculosis: an International Consortium) to enable the measurement of MICs of 14 different antituberculosis (anti-TB) compounds for >30,000 clinical Mycobacterium tuberculosis isolates. Unlike the MYCOTB plate, on which the UKMYC5 plate is based, the UKMYC5 plate includes two new (bedaquiline and delamanid) and two repurposed (clofazimine and linezolid) compounds. UKMYC5 plates were tested by seven laboratories on four continents by use of a panel of 19 external quality assessment (EQA) strains, including H37Rv. To assess the optimal combination of reading method and incubation time, MICs were measured from each plate by two readers, using three methods (mirrored box, microscope, and Vizion digital viewing system), after 7, 10, 14, and 21 days of incubation. In addition, all EQA strains were subjected to whole-genome sequencing and phenotypically characterized by the 7H10/7H11 agar proportion method (APM) and by use of MGIT960 mycobacterial growth indicator tubes. We concluded that the UKMYC5 plate is optimally read using the Vizion system after 14 days of incubation, achieving an interreader agreement of 97.9% and intra- and interlaboratory reproducibility rates of 95.6% and 93.1%, respectively. The mirrored box had a similar reproducibility. Strains classified as resistant by APM, MGIT960, or the presence of mutations known to confer resistance consistently showed elevated MICs compared to those for strains classified as susceptible. Finally, the UKMYC5 plate records intermediate MICs for one strain for which the APM measured MICs close to the applied critical concentration, providing early evidence that the UKMYC5 plate can quantitatively measure the magnitude of resistance to anti-TB compounds that is due to specific genetic variation. (Copyright © 2018 Rancoita et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu